Regular dosage of selegiline has no effect on kidney function, but as selegiline is mainly excreted through the kidneys, high dosage of selegiline will increase the burden on the kidneys and affect kidney function. Sitagliptin is a dipeptidyl peptidase 4 inhibitor, which can improve the function of pancreatic islet β-cells, and increase the level of active enteric islet stimulating hormone to control hyperglycemia, especially for postprandial blood glucose control effect is good. It is mainly used in the treatment of type 2 diabetes mellitus. The main adverse effects of selegiline include digestive symptoms such as abdominal pain, diarrhea, nausea and vomiting, nasopharyngitis and urinary tract infections. Renal insufficiency is not a contraindication to the use of this drug, but you need to adjust the dosage according to renal function, mild renal insufficiency does not need to be adjusted, moderate and severe renal insufficiency need to be reduced under the guidance of a specialist physician. It should be noted that selegiline is not recommended for patients with a history of pancreatitis, and should be stopped immediately if symptoms of pancreatitis are suspected during use. In addition, the risk of hypoglycemia is increased when used in combination with insulin stimulation, and the dosage needs to be reduced appropriately. Selegiline should be used under medical supervision, do not self-medicate.